Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
AssigneeKrystal Biotech, Inc.
InventorsSuma Krishnan, Pooja Agarwal
Life of this patent
Estimating the term…
Abstract
The present disclosure relates, in part, to pharmaceutical compositions comprising one or more polynucleotides suitable for enhancing, increasing, augmenting, and/or supplementing the levels of Collagen alpha-1 (VII) chain polypeptide and/or Lysyl hydroxylase 3 polypeptide and/or Keratin type I cytoskeletal 17 polypeptide in a subject. The present disclosure also relates, in part, to pharmaceutical compositions and methods of use for providing prophylactic, palliative, or therapeutic relief of a wound, disorder, or disease of the skin in a subject, including a subject having, or at risk of developing, one or more symptoms of epidermolysis bullosa.
Claims36
A pharmaceutical composition useful for topical, transdermal, subcutaneous, and/or intradermal treatment of skin wounds in a subject comprising:
- a) a herpes simplex virus (HSV) comprising a recombinant herpes simplex virus genome, wherein the recombinant herpes simplex virus genome comprises one or more transgenes encoding a polypeptide selected from the group consisting of a Collagen alpha-1 (VII) chain polypeptide, a Lysyl hydroxylase 3 polypeptide, a Keratin type I cytoskeletal 17 polypeptide, and a chimeric polypeptide thereof;
- and
- b) a pharmaceutically acceptable carrier;
- wherein the HSV has reduced cytotoxicity as compared to a wild-type herpes simplex virus.
A method of providing prophylactic, palliative, or therapeutic relief of a wound, disorder, or disease of the skin in a subject, the method comprising administering to the subject a pharmaceutical composition comprising:
- a) a herpes simplex virus (HSV) comprising a recombinant herpes simplex virus genome, wherein the recombinant herpes simplex virus genome comprises one or more transgenes encoding a polypeptide selected from the group consisting of a Collagen alpha-1 (VII) chain polypeptide, a Lysyl hydroxylase 3 polypeptide, a Keratin type I cytoskeletal 17 polypeptide, and a chimeric polypeptide thereof;
- and
- b) a pharmaceutically acceptable carrier;
- wherein the HSV has reduced cytotoxicity as compared to a wild-type herpes simplex virus.
Dependencies are inferred from the claim text.